India  

Juul Ordered to Pay $440 Million in Teen Vaping Settlement

Video Credit: Wibbitz Top Stories - Duration: 01:31s - Published
Juul Ordered to Pay $440 Million in Teen Vaping Settlement

Juul Ordered to Pay $440 Million in Teen Vaping Settlement

Juul Ordered to Pay , $440 Million, in Teen Vaping Settlement.

Electronic cigarette maker Juul Labs will pay a $440 million settlement to end a two-year investigation into the company's marketing of its vaping products.

'The Guardian' reports that the 33-state investigation comes after the company was blamed for sparking a national surge in teen vaping.

The nearly $440 million deal was announced on September 6 by William Tong, the Connecticut attorney general.

The nearly $440 million deal was announced on September 6 by William Tong, the Connecticut attorney general.

The investigation reportedly looked into Juul's early promotions and claims regarding the safety and benefits of its product as a smoking alternative.

The investigation reportedly looked into Juul's early promotions and claims regarding the safety and benefits of its product as a smoking alternative.

Following the settlement, Juul still faces nine separate lawsuits from other states.

In addition to these state lawsuits, the company is also facing hundreds of personal suits brought on behalf of consumers who say they became addicted to the company's products.

In addition to these state lawsuits, the company is also facing hundreds of personal suits brought on behalf of consumers who say they became addicted to the company's products.

Through this settlement, we have secured hundreds of millions of dollars to help reduce nicotine use and forced Juul to accept a series of strict injunctive terms to end youth marketing and crack down on underage sales, William Tong, Connecticut attorney general, via 'The Guardian'.

'The Guardian' reports that the $438.5 million settlement will be paid out over a period of six to ten years.

This summer, the Food and Drug Administration moved to ban all Juul vaping products from the market.

.

An ongoing FDA review is one part of a sweeping effort to regulate the multimillion-dollar vaping industry following years of regulatory delay


You Might Like


💡 newsR Knowledge: Other News Mentions

Food and Drug Administration Food and Drug Administration Agency of the US Department of Health and Human Services

'Artificial Tears': US CDC issues advisory against India-made eye-drop | Explainer | Oneindia News [Video]

'Artificial Tears': US CDC issues advisory against India-made eye-drop | Explainer | Oneindia News

The US FDA has issued advisory against using ‘Artificial Tears’…an eye drop manufactured by an Indian pharmaceutical company. This is the third such incident in the recent times in which Indian pharmaceutical companies have been in the crosshairs of health authorities. Just few months back, a controversy had erupted over the death of 66 children in Gambia after taking cough syrup imported from India. Then, towards the end of December, Uzbekistan had also claimed that 18 of 21 children with acute respiratory diseases died after ingesting Dok-1 Max syrup…a syrup that was manufactured and exported to Uzbekistan. In this video, we take a look at the possible reasons why the US FDA has issued caution over an India-made eye drop. But before that, don’t forget to like, share and subscribe to Oneindia #USFDA#artificialtearseyedrop #USAbansindiaeyedrop

Credit: Oneindia    Duration: 03:43Published
FDA Proposes Annual COVID Vaccination Plan [Video]

FDA Proposes Annual COVID Vaccination Plan

FDA Proposes , Annual COVID Vaccination Plan. ABC reports that health officials in the United States want to make COVID-19 vaccinations more like the annual flu shot. On January 23, the Food and Drug Administration proposed a new vaccination effort that would allow most adults and children to get a once-a-year COVID shot. ABC points out that this means people in the U.S. would no longer have to keep track of how many shots they've received or when they last got boosted. According to ABC, the proposal comes as over 80% of the U.S. population has received at least one dose of the vaccine, while just 16% have received the latest booster. On January 26, the FDA will refer to a panel of outside vaccine experts to weigh the new proposal. According to FDA scientists, many Americans now have “sufficient preexisting immunity” because of vaccination, infection or a combination of the two. . Scientists at the FDA and vaccine companies suggest that further study could be done to decide who should receive a single shot and who requires a two-dose series. The FDA plan also includes streamlining the process by switching all vaccines to target the same strains, thus eliminating the current complicated system. The proposal also includes a similar approach to the annual flu shot by having the agency, independent experts and manufacturers select which strains to target annually. The FDA has expressed that the move to an annual schedule would also help promote future vaccination campaigns and boost nationwide vaccination rates

Credit: Wibbitz Top Stories    Duration: 01:31Published